ライフサイエンスコーパス: iliofemoral

1 Plaques were most common in the iliofemorals (44%), followed by the carotids (31%) and a

2 ssment of the aortic root, evaluation of the iliofemoral access route, and prediction of appropriate

3 signed to SAVR or TAVR (transfemoral [TF] if iliofemoral access was suitable or transapical [TA] if n

4 We evaluated ultrasound-detected carotid, iliofemoral, and abdominal aortic plaques; coronary arte

5 site (right/left carotids, aorta, right/left iliofemorals, and coronary arteries).

6 related complication (SRC) was defined as an iliofemoral arterial injury not including a cannulation

7 ned with intravenous streptokinase, 10 of 17 iliofemoral arteries (59%) treated with transcutaneous u

8 Pairs of iliofemoral arteries in 10 rabbits were randomized to re

9 Balloon-mediated injury of iliofemoral arteries in rabbits resulted in prominent de

10 tion was induced electrically in 48 pairs of iliofemoral arteries of 24 rabbits; arterial occlusions

11 PC) on neointimal lesions in balloon-injured iliofemoral arteries of hypercholesterolemic rabbits.

12 All 10 iliofemoral arteries treated with PESDA + ultrasound wer

13 7 of 24 rabbits, 14 thrombotically occluded iliofemoral arteries were exposed to ultrasound alone wi

14 The pairs of iliofemoral arteries were randomized to receive ultrasou

15 ft carotids, abdominal aorta, right and left iliofemoral arteries, and coronary arteries.

16 ysis of thrombi with streptokinase in rabbit iliofemoral arteries.

17 a higher incidence of aneurysm formation and iliofemoral artery injury than surgery.

18 ristic models were generated using sheath-to-iliofemoral artery ratios as a variable and SRC as an en

19 s underwent balloon denudation injury of the iliofemoral artery.

20 rolled clinical trial of patients with acute iliofemoral deep vein thrombosis treated with a fixed-do

21 n age 50 +/- 21 years, 52% women) with acute iliofemoral deep vein thrombosis were randomized to rece

22 For patients with acute iliofemoral deep vein thrombosis, it remains unclear whe

23 Iliofemoral disease was the indication for 584 procedure

24 Iliofemoral DVT (n = 221 [71%]) and femoral-popliteal DV

25 Patients with acute iliofemoral DVT represent a subgroup at particularly hig

26 ne therapy for patients with extensive acute iliofemoral DVT, low expected bleeding risk, and good fu

27 ine therapy for selected patients with acute iliofemoral DVT.

28 omputed tomography (CT) is commonly used for iliofemoral evaluation for transfemoral transcatheter ao

29 roposed as an effective treatment of chronic iliofemoral (I-F) and inferior vena cava (IVC) thrombosi

30 insufficiency, especially when the proximal iliofemoral is involved.

31 ction in extension; the superior band of the iliofemoral ligament was best evaluated in the coronal a

32 The inferior band of the iliofemoral ligament was best evaluated in the sagittal,

33 degree of sheath oversizing with respect to iliofemoral minimal artery diameter and female sex are a

34 ), renal (n = 7), mesenteric (n = 2), and/or iliofemoral (n = 9) malperfusion syndrome were included.

35 HU) of the aorta and intense enhancement of iliofemoral runoff was achieved without venous contamina

36 Endovenous recanalization of iliofemoral stenosis or occlusion with angioplasty and s

37 gregation, whereas a healthy rabbit model of iliofemoral stent implantation was used to assess re-end

38 ing, four patients underwent placement of an iliofemoral stent, and one patient underwent placement o

39 erosis in the carotid, abdominal aortic, and iliofemoral territories by 2-/3-dimensional ultrasound a

40 We evaluated the long-term impact of iliofemoral thrombosis (I-FDVT) on walking capacity, ven

41 than conventional treatment in patients with iliofemoral vein thrombosis.

42 of stent reconstruction of stenotic/occluded iliofemoral veins (IFV) and inferior vena cava (IVC).

43 rial switch operation (n = 7); 2) those with iliofemoral venous obstruction (n = 6); and 3) those wit

44 Stent placement for iliofemoral venous outflow obstruction results in high t

45 tiveness of stent placement in patients with iliofemoral venous outflow obstruction.

46 s of venous stent placement in patients with iliofemoral venous outflow obstruction.

47 in long-term venous patency in patients with iliofemoral venous outflow obstruction.

48 Kaplan-Meier analysis showed primary iliofemoral venous patency rates at 1, 3, and 5 years of

49 ifty-one consecutive patients with extensive iliofemoral venous thrombosis were treated during a 10-y

50 es have reported on conventional therapy for iliofemoral venous thrombosis with disappointing results

51 rtion of candidates for TAVR have inadequate iliofemoral vessels for TF access.